Novavax Inc stated its two-dose Covid-19 vaccine showed “strong immune responses” against the Omicron variant, according to a press release by Novavax on Wednesday.
- The company stated that neutralization against the Omicron variant was “4-fold lower” than it was against the original version of the virus, signaling that a booster shot would be beneficial.
- The Maryland-based company stated that a third vaccine short six months after the two doses signaled an increase in antibodies to levels related to protection recorded in earlier large clinical trials.
- Gregory Glenn, Novavax’s president of research and development stated they are encouraged that boosted responses against variants were comparable to those linked to high vaccine efficacy in Phase 3 clinical trials.
- Glenn further stated that Novavax has closed and characterized the Omicron spike protein vaccine and will soon progress to the GMP-phase of production.
Early in the week, Novavax’s vaccine received a major endorsement from the European Medicines Agency. NVAX up +5.70%